Shopping Cart

Your shopping cart is currently empty

Ethambutol

Name: Ethambutol
Brand: TargetMol
SKU: T7062
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T7062Cas No. 74-55-5

Alias Myambutol, EMB

Ethambutol is an oral anti-tuberculosis drug that inhibits arabinosyl transferase activity, thereby interfering with the synthesis of arabinogalactan and preventing cell wall formation to exert its antibacterial effect; it can also be used for animal models of hyperuricemia and optic neuropathy.

Ethambutol

Copy Product Info

😃Good

Purity: 99.92%

Catalog No. T7062Alias Myambutol, EMBCas No. 74-55-5

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$31	-	In Stock
10 mg	$54	-	In Stock
25 mg	$109	-	In Stock
50 mg	$185	-	In Stock
100 mg	$313	-	In Stock
1 mL x 10 mM (in DMSO)	$35	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.92%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Ethambutol is an oral anti-tuberculosis drug that inhibits arabinosyl transferase activity, thereby interfering with the synthesis of arabinogalactan and preventing cell wall formation to exert its antibacterial effect; it can also be used for animal models of hyperuricemia and optic neuropathy.
Targets&IC50	HT29 cells:25.5±4.7 µg/mL, HCT116 cells:5.5±1.0 µg/mL, SW620 cells:5.5±2.1 µg/mL, SW480 cells:5.8±1.3 µg/mL, DLD1 cells:7.8±2.2 µg/mL, MCF-7 cells:11.1±1.1 µg/mL
In vitro	The MTT or CCK-8 assays showed that Ethambutol (0-50µg/mL) exerted a time-dependent inhibitory effect on cell proliferation in six cell lines, including SW480 and SW620. The IC50 values for different cell lines ranged from 5.37 to 31.54µg/mL over 24-72 hours[1]. In the RGC-5 retinal ganglion cell experiment, after treating the cells with 4mM Ethambutol for 8 hours, flow cytometry and Western blot analysis confirmed a significant increase in cell apoptosis, as well as upregulation of autophagy markers such as PI3C3 and Beclin-1[2]. Additionally, treatment of Mycobacterium smegmatis with 10µg/mL Ethambutol followed by acid hydrolysis combined with HPLC and enzyme activity analysis showed changes in arabinogalactanase activity[3].
In vivo	Ethambutol (250 mg/kg, administered by gavage once daily for 23 days) can induce hyperuricemia and cause pathological damage and inflammatory reactions in the thymus and spleen, manifested by thymic atrophy, fusion of the cortex and medulla, congestion of the splenic sinuses, and hemosiderin deposition [4,5]. In addition, Ethambutol (35 mg/kg/day, orally for 30 days) can induce optic neuropathy, leading to ganglion cell damage, increased retinal ganglion cell (RGC) density, and thickening of the RGC layer [6].
Disease Modeling Protocol	Hyperuricemia model Modeling Mechanism： Ethambutol inhibits renal uric acid excretion, reduces uric acid excretion, and synergistically with adenine to significantly increase serum uric acid (UA) levels; ③ Uric acid accumulation further activates the PAR2/PI3K/AKT/NF-κB signaling pathway, inducing renal interstitial inflammation and tubular damage, mimicking the core pathophysiological process of human hyperuricemia. Related Products： Ethambutol (T7062) Modeling Method： Experimental Subject：Rats, Sprague-Dawley (SD), Male, Body weight 200–220 g Dosage and Administration Route：① Core modelling: Adenine (200 mg/kg)+Ethambutol (250 mg/kg), Suspension prepared by dissolving in physiological saline, Administered via gastric lavage; ② Control treatment: Equal volume saline solution, administered via gastric lavage using the same method; ③ Intervention validation (optional): PAR2 antagonist AZ3451 (1 mg/kg) – intraperitoneal injection – administered continuously for 6 weeks post-modelling. Dosing Frequency and Duration Model：Once daily for 4 consecutive weeks Validation： Key indicators (serum biochemistry): - Serum uric acid (UA): The baseline UA in the model group was 110 μmol/L, which increased approximately 2.5-fold after modeling (p<0.05); - XOD activity: The model group showed significantly higher activity than the control group, indicating increased uric acid production; - Renal function indicators: Serum creatinine (Cr) and blood urea nitrogen (BUN) levels were significantly elevated, and the expression of kidney injury markers KIM-1 and NGAL was upregulated (p<0.05); Pathological indicators: - HE staining showed degeneration and necrosis of renal tubular epithelial cells, luminal dilation, and extensive infiltration of inflammatory cells in the renal interstitium in the model group, with brown needle-like crystal deposits visible in some renal tubules; Molecular indicators: - Significantly upregulated mRNA and protein expression of PAR2, PI3K, AKT, and NF-κB in renal tissue (p<0.05); - Inflammatory factors: Elevated levels of pro-inflammatory factors such as TNF-α, IL-6, MCP-1, and IL-1β in renal tissue (ELISA detection, p<0.05); Metabolomics indicators: - Disorders of plasma phospholipid metabolism, with significant differences in 27 phospholipid metabolites (e.g., increased PI metabolites and decreased LPC metabolites). The PCA/OPLS-DA model showed clear separation between the model group and the control group. Precautions： At the end of the experiment, euthanasia was performed by intraperitoneal injection of pentobarbital (100 mg/kg). References：Sui X,et,al. Protease-Activated Receptor-2 and Phospholipid Metabolism Analysis in Hyperuricemia-Induced Renal Injury. Mediators Inflamm. 2023 Jul 13;2023:5007488.
Synonyms	Myambutol, EMB

Chemical Properties

Molecular Weight	204.31
Formula	C₁₀H₂₄N₂O₂
Cas No.	74-55-5
Smiles	[C@H](NCCN[C@@H](CC)CO)(CC)CO
Relative Density.	1.0048 g/cm3 (Estimated)

Storage & Solubility Information

Storage

keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (391.56 mM), Sonication is recommended.

H2O: 180 mg/mL (881.01 mM), Sonication is recommended.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	4.8945 mL	24.4726 mL	48.9452 mL	244.7262 mL
5 mM	0.9789 mL	4.8945 mL	9.7890 mL	48.9452 mL
10 mM	0.4895 mL	2.4473 mL	4.8945 mL	24.4726 mL
20 mM	0.2447 mL	1.2236 mL	2.4473 mL	12.2363 mL
50 mM	0.0979 mL	0.4895 mL	0.9789 mL	4.8945 mL
100 mM	0.0489 mL	0.2447 mL	0.4895 mL	2.4473 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc